SCHEMBL1468141

SCHEMBL1468141

Cc1cc(S(=O)(=O)c2ccccn2)c(C=O)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C1S P09871 1/20 0.44
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
LOX P28300 1/20 0.41
KDM4E B2RXH2 3/20 0.40
PKM P14618 1/20 0.40
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 2/20 0.36
THRB P10828 2/20 0.36
CNR1 P21554 2/20 0.35
ABCC9 O60706 1/20 0.34
ABCC8 Q09428 1/20 0.34
KCNJ11 Q14654 1/20 0.34
KCNJ8 Q15842 1/20 0.34
NFE2L2 Q16236 2/20 0.34
MAPT P10636 1/20 0.34
TXNRD1 Q16881 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1466371 0.83 PKM (0.47) C1SMAOAMAOBLOXKDM4E
SCHEMBL1465851 0.78 HTR6 (0.41) C1SKDM4EPKMMEN1KMT2A
SCHEMBL1421877 0.75 KDM4E (0.43) C1SMAOAMAOBLOXKDM4E
SCHEMBL3717602 0.72 THRB (0.41) C1SMAOAMAOBLOXKDM4E
SCHEMBL13811756 0.71 KDM4E (0.50) C1SMAOAMAOBLOXKDM4E
SCHEMBL13749682 0.70 LOX (0.61) C1SMAOAMAOBLOXKDM4E
SCHEMBL1466494 0.70 KDM4E (0.43) C1SMAOAMAOBLOXKDM4E
SCHEMBL1673906 0.69 KDM4E (0.64) C1SMAOAMAOBLOXKDM4E
SCHEMBL22990174 0.68 KDM4E (0.58) C1SMAOAMAOBLOXKDM4E
SCHEMBL3717392 0.67 PKM (0.47) C1SMAOAMAOBLOXKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225617-A1 INDOLES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-08-29 US disclosed
US-8394836-B2 Indoles and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2013-03-12 US disclosed
EP-2327693-B9 Indoles and their therapeutic use PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-10-24 EP disclosed
EP-2327693-B1 Indoles and their therapeutic use PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-06-20 EP disclosed
EP-2327693-A1 Indoles and their therapeutic use Pulmagen Therapeutics (Asthma) Limited (GB) 2011-06-01 EP disclosed
US-20110071175-A1 Indoles and Their Therapeutic Use GB005, INC. 2011-03-24 US disclosed
EP-2229358-A1 INDOLES AND THEIR THERAPEUTIC USE Pulmagen Therapeutics (Asthma) Limited (GB) 2010-09-22 EP disclosed
WO-2009077728-A1 INDOLES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225617-A1 INDOLES AND THEIR THERAPEUTIC USE IDO2, IDO1, RORB C1S 3233/4885MAOA 654/4885MAOB 728/4885
US-20110071175-A1 Indoles and Their Therapeutic Use FPR3, HRH2, HRH4 C1S 439/4885MAOA 1524/4885MAOB 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.